Mike Havrilla
Long-term horizon

BioSpecifics Poised For Run Up Into Near-Term FDA Catalyst

BioSpecifics Technologies (NASDAQ:BSTC) (click here for most recent presentation) is focused on the development of injected biological agent (collagenase/XIAFLEX) for a variety of indications in collaboration with Auxilium Pharma (NASDAQ:AUXL) as a marketing and development partner in an agreement that results in BSTC receiving royalties, mark-up on cost of goods sold and licensing revenue.


XIAFLEX (AA4500) (collagenase clostridium histolyticum) is being evaluated in multiple clinical trials and also has a near-term FDA catalyst in the form of a 6-September PDUFA data for a supplemental Biologics License Application (sBLA) seeking the FDA approved label for the product.

The sBLA is undergoing a standard review by the FDA and is...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details